Progress in the study about androgen receptor splicing variants 7 and the drug resistant of prostate cancer

Prostate cancer is an urogenital malignancy which is common in older men. Androgen deprivation therapy is an usual treatment for metastatic prostate cancer significantly inhibiting the progression of advanced prostate cancer via blocking androgen synthesis, or competitive binding to androgen receptors. Nevertheless, most of the patients end up with metastatic castration-resistant prostate cancer (mCRPC) on the account of androgen resistance. It has been shown that androgen receptor splice variant 7 is strongly associated with the development of mCRPC and its drug resistance to androgen receptor signal transduction inhibitors (enzalutamide and abiraterone) in studies of recent years. Key words: Metastatic castration-resistant prostate cancer; Androgen-receptor splice variant 7; Drug resistance to androgen deprivation therapy